Clinical Trials
2 trialsNCT07169331 2025-12-19
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
BeOne Medicines
Phase 4 Recruiting
NCT04042376 2025-05-25
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
Janssen Research & Development, LLC
Phase 4 Completed